ALXN1210

Analysts at Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Thursday despite the stock's 17-percent loss year to date and two management shake-ups in the past six months alone. Morgan Stanley's Matthew Harrison upgraded Alexion's stock rating from Equal Weight to Overweight...